Literature DB >> 26241670

Mohs Surgery for Squamous Cell Carcinoma of the Nail Unit: 10 Years of Experience.

Emi Dika1, Pier Alessandro Fanti, Annalisa Patrizi, Cosimo Misciali, Sabina Vaccari, Bianca Maria Piraccini.   

Abstract

BACKGROUND: Squamous cell carcinoma (SCC) is the most frequent malignant tumor of the nail unit.
OBJECTIVE: The aim of this study was to review the long-term outcome of patients affected by SCC of the nail who underwent Mohs surgery.
MATERIALS AND METHODS: Patients affected by nail SCC were enrolled, including cases where x-ray examination had revealed bone changes. The tumor was completely excised and the defect filled with a skin substitute based on hyaluronic acid where bone involvement was not observed. Where Mohs sections indicated bone involvement, the distal phalanx was disarticulated and the remaining end of the digit repaired using a volar/plantar flap. Follow-up was performed every 6 months for 5 years.
RESULTS: Mohs technique was performed in 43 cases. Microinvasive SCC was diagnosed in 5 cases, in situ SCC in 7 cases, and invasive SCC in 45 patients. Recurrences were observed in 2 patients (3.5%). Disarticulation was performed in both of them, and no further tumor recurrences were observed in 4 to 5 years of follow-up.
CONCLUSION: Mohs surgery provides the highest cure rate for the treatment of nail SCC. It allows the evaluation of periosteal invasion and therefore bone invasion to be reliably distinguished from inflammation or compression. This technique reduces the number of unnecessary amputations, a critical consideration for patient's quality of life.

Entities:  

Mesh:

Year:  2015        PMID: 26241670     DOI: 10.1097/DSS.0000000000000452

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  11 in total

Review 1.  Dermatology Roundup: The Latest Tips, Techniques, and Technologies for Busy Clinicians.

Authors:  Ted Rosen
Journal:  J Clin Aesthet Dermatol       Date:  2017-03-01

Review 2.  Skin substitutes for the management of mohs micrographic surgery wounds: a systematic review.

Authors:  Kimberly W Lu; Amor Khachemoune
Journal:  Arch Dermatol Res       Date:  2022-02-15       Impact factor: 3.017

Review 3.  Dermoscopic Evaluation of Inflammatory Nail Disorders and Their Mimics.

Authors:  Sophie Soyeon Lim; Alex Chamberlain; Keunyoung Hur; Jungyoon Ohn; Byeol Han; Victoria Mar; Je-Ho Mun
Journal:  Acta Derm Venereol       Date:  2021-09-15       Impact factor: 3.875

Review 4.  The Diagnosis and Treatment of Nail Disorders.

Authors:  Uwe Wollina; Pietro Nenoff; Gunter Haroske; Holger A Haenssle
Journal:  Dtsch Arztebl Int       Date:  2016-07-25       Impact factor: 5.594

5.  Secondary-intention healing following Mohs micrographic surgery for squamous cell carcinoma of a finger.

Authors:  Julio Magliano; Virginia Rossi; Nelson Turra; Carlos Bazzano
Journal:  Int Wound J       Date:  2018-08-30       Impact factor: 3.315

6.  Subungual Squamous Cell Carcinoma: The Diagnostic Challenge and Clinical Pearls.

Authors:  Wai Leong Kok; Joyce Siong See Lee; Martin Tze-Wei Chio
Journal:  Case Rep Dermatol       Date:  2016-10-13

7.  Squamous Cell Carcinoma of the Nail Bed.

Authors:  Dan-Dan Mao; Guang-Dong Wen; Zhang-Lei Mu; Meng Cao; Jian-Zhong Zhang; Xue Chen
Journal:  Chin Med J (Engl)       Date:  2017-04-05       Impact factor: 2.628

8.  Squamous cell carcinoma of the nail unit.

Authors:  Michela Starace; Aurora Alessandrini; Emi Dika; Bianca Maria Piraccini
Journal:  Dermatol Pract Concept       Date:  2018-07-31

9.  Subungual Invasive Squamous Cell Carcinoma with Doubtful Underlying Bone Invasion: A Treatment Proposal.

Authors:  Judith Dominguez-Cherit
Journal:  Skin Appendage Disord       Date:  2020-11-24

10.  Reconstruction for Defects of Total Nail Bed and Germinal Matrix Loss with Acellular Dermal Matrix Coverage and Subsequently Skin Graft.

Authors:  Tsung-Hsien Liu; Meng-Chien Hsieh; Ping-Ruey Chou; Shu-Hung Huang
Journal:  Medicina (Kaunas)       Date:  2020-01-03       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.